News
-
-
-
-
-
-
-
-
-
-
PRESS RELEASE
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Jaguar Health, Inc. discusses developing oral crofelemer for pediatric patients with Intestinal Failure (IF) due to MVID, aiming for Breakthrough Therapy Designation. Initial results show reductions in PS needs